Searched for
BUDESONIDE
Glenmark launches fixed-dose triple therapy for COPDGlenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three...- Amid pollution woes, Asthma drug demand drives pharma retail market growth in NovemberIndia's pharmaceutical retail market rebounded in November with double-digit growth, fueled by increased demand for dermatological, cardiac...
- Mankind Pharma enters exclusive pact to distribute AstraZeneca's anti-asthma drug Symbicort in IndiaAstraZeneca Pharma India has partnered with Mankind Pharma to exclusively distribute its anti-asthma drug Symbicort in India. AstraZeneca w...
- Surge in viral infections pushes up pharma salesThe volumes were tepid in January, but with flu, Covid-19 and other viral infections spreading fast, February and March saw spikes in volum...
- 2 yrs on, vaccines, following protocols remain most effective weapons against COVID-19As India completed two years since the outbreak of COVID-19, vaccines and following COVID Appropriate Behaviour remain the most effective w...
- Go for test for TB, other conditions if cough persists for more than 2-3 weeks: Revised clinical guidance for Covid patientsThe revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...
- Covid treatment: Govt issues revised guidelines on use of drugs, therapiesThe revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...
- One year on, vaccines still most acceptable weapon against COVID-19Even though vaccines remain to be the only acceptable weapon against the deadly virus, a number of drugs and other methods, including chant...
- We can expect more COVID drugs next year. But we've wasted so much time getting hereIt's inevitable some existing drugs trialled initially for COVID-19 would fall by the wayside and never be used clinically. But we backed s...
- Pfizer's pill is the latest COVID treatment to show promise. Here are some moreAccording to Pfizer's trial results, Paxlovid could be used as an alternative to in-hospital treatment for preventing disease progression i...
- Health Ministry releases revised guidelines for home isolation of mild COVID-19 casesElderly patients aged more than 60 years and those with co-morbid conditions such as hypertension, diabetes, heart disease, chronic lung or...
- Lupin gets USFDA nod for Asthma drugQuoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.
- USFDA gives final approval to Cipla's anti-asthma productCiting IMS Health data, Cipla said Pulmicort Respules and generic equivalents had US sales of approximately USD 825 million for the 12 mont...
- AstraZeneca gets marketing nod for asthma drug SymbicortResults from AstraZeneca's two clinical studies have shown that the addition of formoterol to budesonide improved asthma symptoms and lung ...
- Natco Pharma gets USFDA nod for generic Budesonide capsulesThe company has received "final approval of abbreviated new drug application from the US Food and Drug Administration for generic version o...
- Over 200 drugs under development, top 50 with $30 billion potential: CiplaElaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...
- Teva-Allergan deal may divest products worth $600 millionAs Israeli drugmaker Teva readies to acquire Allergan as part of its recent $40.5-billion deal, a large bounty of products is expected to b...
- Cipla gains as partner Sandoz gets USFDA approval for generic drugCipla surged over 4% in trade after its partner Sandoz received a USFDA nod to launch a generic version of Pulmicort respules.
Load More
